Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2656 to 2670 of 2854 results for process

  1. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

  2. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

  3. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

  4. The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (HTG566)

    Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal.

  5. Data collection agreement

    tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor will use the process and methods in place at the time of the invitation to...

  6. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  7. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  8. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  9. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

  10. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  11. Social, emotional and mental wellbeing in primary and secondary education (NG223)

    This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.

  12. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

  13. Medical technologies evaluation programme methods guide (PMG33)

    This medical technologies evaluation programme methods guide has been replaced by the NICE HealthTech programme manual.

  14. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  15. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC